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Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321S316All the patients are alive in remission at the present timewith
median post SCT survival of 9.4 months (2.1-18.5).
Conclusion: Posttransplant Rux appears to be safe and
feasible. Further investigation is warranted to elucidate
whether improved outcomes are due to a direct effect on the
primary marrow disorder, alleviation of the constitutional
symptoms or GvHD.Figure.457
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Background: Primary graft failure (pGF) after cord blood
transplantation (CBT) still occurs in roughly 10% of cases.
Although associated with a poor prognosis, cases diagnosed
early have an increased possibility of rescue with re-trans-
plantation. We considered an early stage diagnostic method
by elucidating mechanisms underlying post-CBT pGF.
Patients and Method: We analyzed 105 cases of single-unit
CBT at our institution. For pGF cases, we analyzed WBC dy-
namics (neutrophils, lymphocytes), chimerism, and fever,
and compared these parameters with delayed (>day 28) or
normal (day 28) engraftment cases.
Results: Of the evaluable 102 cases, 59 were normal engraft-
ment cases, 33 were delayed engraftment cases, and 10 were
pGF cases. Of the 10 pGF cases, 7 showed essentially no blood
cell count recoverybyday14, andsudden lymphocyte recovery
at amedian of day 18 (range,15-24) followedbygraft rejection.
Of the 4 assessed for chimerism at the time of lymphocyte in-
crease, all showed recipient-derived cells. 3 of the 10 pGF cases
never achievedWBC100/mL byday28. For engraftment cases,
lymphocyte number peaked at day 12, and almost cases
assessed for chimerism showed donor-derived cells. Only 1 of
the 67 cases which showedWBC>100/mL on day 12 indicated
pGF, whereas pGF was observed in 9 of the 33 cases in which
WBC was <100/mL (p<0.001). 72 cases had febrile episodes
which were associated with pre-engraftment immune reac-
tion. Theproportionof febrile (38C)casespeakedatday8 for
normal engraftment cases, day 11 for delayed engraftment
cases, and day 12.5 for pGF cases.
Conclusions: pGF likelihood should be considered for cases
of delayed timing of non-infectious fever, cases for which
WBC recovery is not seen at around day 12, and cases of
sudden lymphocyte recovery at around day 18.Table.
Age Sex Disease Prior
Auto
N prior
therapies
Status at
transplant
Donor CD34 dose 1
(x10e6/kg)
CD
(x
41 M FL Yes 4 CR MRD 3.18
87 M DLBCL Yes 3 PO MUD 1.9
64 M DLBCL No 2 PR MUD 1.84
54 F MCL No 2 PR MUD 10.19
52 M DLBCL Yes 4 PR MRD 2.94
69 M FL Yes 5 PR MUD 10.39
39 M DLBCL No 2 PR MUD 6.87
35 F DLBCL No 2 PR MRD 5.87
61 M DLBCL No 2 CR MMRD 7.9
46 F DLBCL No 1 CR MMUD 4.03 11458
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A subset of patients with advanced or relapsed B-cell lym-
phomas can be cured with allogeneic hematopoietic cell
transplantation (allo-HCT), but success is hampered by the
risk of recurrence and GVHD. Here we report the results of a
phase 2, single center trial combining anti-CD20 radio-
immunotherapy (RIT) with I-131 tositumomab and mTOR
inhibitionwith sirolimus for prevention of serious GVHD and
reduction in risk of relapse. Subjects (n¼10) received I-131
tositumomab 75cGi therapeutic dose on day -12, ﬂudarabine
25 mg/m2 IV on days -6 to -2 and melphalan 70 mg/m2 IV on
days -3 and -2 followed by peripheral blood grafts from 7/8
or 8/8 HLA matched related or unrelated donors. GVHD
prophylaxis consisted in sirolimus 12 mg PO loading dose on
day -14 in order to overlap with the conditioning regimen,
then 4mg PO daily with target blood level of 3-12 ng/ml, and3 dose
10e8/kg)
aGVHD
max
grade
cGVHD Time of
relapse
(months)
Follow-up
(months)
Outcome
3.38 3 Yes 8.9 18.4 Death from disease
0.3 0 Yes 63.6 Alive
2.97 0 Yes 60.8 Alive
3.57 0 Yes 10.2 Death from PE
4.22 0 Yes 9.3 33.0 Death from disease
1.61 0 Yes 13.6 25.1 Alive
2.24 0 No 17.1 18.0 Alive after relapse
3.01 0 No 4.5 14.0 Alive after relapse
3.01 0 Yes 9.8 Alive
2 0 Yes 8.9 Alive
Figure 1. Higher symptom burden associated with increased median viral
load
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10 ng/ml. In absence of signiﬁcant GVHD, tacrolimus was
tapered between days 60 and 100 and sirolimus between
days 100 and 180. Characteristics of patients are displayed in
Table 1. All patients reached engraftment after a median of 15
days (range 12-22) for neutrophils > 0.5109/L and 18 days
(range 17-44) for platelets >20109/L. There were no deaths
before day +100. 1 patient developed grade III aGVHD and 8
patients developed cGVHD. All patients had complete
chimerism and were in complete remission at day +100
assessment. Median follow up is 18.4 months (8.9-63.6).
There have been 5 relapses and 3 patients received donor
lymphocyte infusion as part of the treatment strategy. 2
patients died from refractory disease, 1 patient died from
pulmonary embolism, 2 patients are alive not in remission
and 5 patients are alive with no evidence of disease. No pa-
tient has died of GVHD or infectious complications. Median
progression free and overall survival are 10.2 (95% C.I. 4.5-
63.6) and 18.4 (95% C.I. 8.9-63.6, Figure 1) months respec-
tively. We conclude that a regimen with RIT and mTOR
inhibition incorporated into allo-HCT could lead to adequate
disease control with low risk of aGVHD. Strategies targeting
host B-cells in combination with mTOR inhibitor should be
explored further in the development of allo-HCT for treat-
ment of advanced B-cell lymphomas.Figure 2. Lower viral load at initial test is associated with lack of symptoms at
time of initial test (A) and throughout viral shedding episode (B).459
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Background: Human rhinovirus (HRV), the virus predomi-
nantly associated with the common cold, is the most
common virus detected from respiratory specimens in he-
matopoietic cell transplant (HCT) recipients, largely due to
the development of new sensitive molecular viral detection
techniques. In immunocompetent children, HRV viral load
from nasal specimens correlates with disease severity,
namely the development of pneumonia, hospital admission,
and oxygen requirement. Prospective studies describing the
relationship between viral load and symptoms in immuno-
compromised hosts, however, are limited.
Methods: We conducted a prospective surveillance study of
allogeneic HCT recipients, in which upper respiratory sam-
ples and symptom surveys were collected weekly for the ﬁrst
100 days following HCT, then every 3 months or with new
respiratory symptoms thereafter for 1 year. Symptom sur-
veys included assessment of 11 respiratory symptoms
including rhinorrhea, sinus congestion, post-nasal drip,
dyspnea, cough, wheezing, sputum production, pharyngitis,
sneezing, watery eyes and ear pain. Respiratory samples
were tested by real-time RT-PCR targeting the highly
conserved 50 noncoding region. RT-PCR cycle threshold (CT)
values were used as a proxy measure of viral load. Only pa-
tients with symptom survey results within 3 days of initial
sample collection were considered eligible for analysis.
Results: Of 471 patients included in the study, 153 (32%)
were positive for HRV at least once during the study dura-
tion; 128 patients had a reported viral load at the initial
positive sample and had a symptom survey completedwithin 3 days of the initial positive sample. Comparison of
median CT values of initial positive samples of patients with
no symptoms, 1-2 symptoms, and 3 or greater symptoms
revealed the presence of fewer symptoms was associated
with higher CT values (i.e. lower viral loads, p¼ 0.036, Figure
1). Patients whose initial CT value was high (35) were more
likely to be asymptomatic at initial positive test result than
patients with lower initial CT values (25-30 and <25) (48%
vs. 26% vs. 17%, p ¼ 0.064, Figure 2A) and were more likely to
remain asymptomatic throughout the viral shedding episode
(27% vs. 7% vs. 9%, p ¼ 0.033, Figure 2B).
Conclusions: No or few symptoms at the time of initial
viral positivity were associated with lower viral loads
